27 Mar 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Singapore-based TriReme Medical has signed a distribution agreement with Weihai Weigao Medical Devices for the distribution of its products in China. Weigao will act as TriReme's master distributor by selling TriReme products directly to hospitals as well as connecting TriReme products into its vast nationwide distribution network.
Dr Eitan Konstantino, CEO and president, TriReme, said that, "Due to many factors including increased affordability, aging population and an increase in the number of state-of-the-art medical facilities, China has become the world's second largest market in terms of the volume of interventional coronary vascular procedures. For similar reasons, we expect that the number of peripheral vascular procedures will rise dramatically in the coming years to the point where China becomes the world's largest market in terms of total vascular interventions."
Ms CHU Swee Yeok, CEO and President, EDBI and Bio*One Capital said, "We are confident that TriReme products and technologies will lead to better clinical outcomes for Chinese patients and are thrilled to partner with a distinguished player like Weigao to introduce TriReme products into the world's fastest growing healthcare market. Such a partnership is a great example of how highly innovative companies like TriReme can leverage on Singapore as a base to access vital Asia markets for their growth."
Mr SUN Feng Wei, general manager, Weigao Medical Devices, said that, "Weigao remains committed to partnering with healthcare providers across China to provide access to best-in-class technology across a wide range of product categories. We view TriReme as a top brand and this partnership allows us to bring the highest quality devices to our growing customer base of physicians performing interventional vascular procedures."